Maddi Hebebrand, MC, Associate Editor

These leaders are shaping the future of dermatology through their clinical expertise, research, and educational presentations.

Guardrails and disclaimers are essential for responsible AI deployment in dermatology, according to Faranak Kamangar, MD.

Misconceptions about vitiligo, including contagion and supernatural causation, remain prevalent in many regions and are linked to increased stigma.

The upcoming trial will assess an injectable formulation of Xvie, distinct from its currently available topical counterpart.

Overall, the future of dermatology lies in integrating innovation with individualized, evidence-based, and patient-centered care.

Successful negotiation integrates compensation, productivity, procedural access, and autonomy to create a sustainable, well-valued clinical role.

In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use.

Phase 2 APEX part A data showed zumilokibart maintained EASI-75 responses in 75–85% of week 16 responders at 1 year across quarterly and biannual dosing regimens.

Swanson and Silverberg explain why tween skin care trends harm barriers, and how clinicians can simplify routines and spot allergens.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Only 15–20% of eligible patients currently receive systemic psoriasis treatment, and specialists believe icotrokinra's simplicity could meaningfully move that needle.

When used thoughtfully, Faranak Kamangar, MD, says AI can transform generic processes into innovative, time-saving clinical tools.

Clinician contract negotiation is often treated as administrative, but it directly affects pay, autonomy, workflow, and career trajectory.

Trainees identified legal, ethical, and reliability concerns as key barriers to integrating AI into dermatology practice.

Clinical trial data showed approximately 70% of patients achieved clear or almost clear skin with icotrokinra by week 16.

New data show that nearly 40% of eczema patients face insurance-related barriers, delaying or preventing access to prescribed therapies.

New top-line results from the BE BOLD trial provide dermatology clinicians with comparative data on 2 biologic therapies targeting different inflammatory pathways in psoriatic arthritis (PsA).

Positive phase 3 findings from ADorable-1 suggest lebrikizumab could expand biologic treatment options for younger patients with atopic dermatitis (AD).

Chovatiya discusses treat-to-target goals, biologics, BSA remission, and patient burden in psoriasis.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Jessica DeLuise, PA-C, MHS, CCMS, joins Derm Dispatch to discuss how nutrition and lifestyle intersect with inflammatory skin disease across clinical settings.

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

Recent reviews highlight that melanoma risk associated with occupational UV exposure varies by tumor subtype, anatomical site, and individual susceptibility.

Compared with topical regimens, Rossi notes PDT provides a shorter recovery window and fewer adherence challenges.

Researchers observed early reductions in acne lesions, with improvements beginning within 5 days of dermocosmetic treatment in patients with acne.

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

A prospective study found that patch testing identified relevant allergens in 43% of patients with hand and foot eczema, with potassium dichromate being the most common sensitizer.

Red light–activated photodynamic therapy offers an effective field-based option for treating both visible and subclinical actinic keratoses.

A survey of dermatology residents found that interest in subspecialty fellowships often declines during training, with financial concerns particularly affecting pediatric dermatology.